Edgewise Therapeutics, Inc.
EWTX
$12.17
-$1.42-10.42%
| Weiss Ratings | EWTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | EWTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | EWTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.99 | |||
| Price History | EWTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -45.35% | |||
| 30-Day Total Return | -55.06% | |||
| 60-Day Total Return | -52.11% | |||
| 90-Day Total Return | -61.96% | |||
| Year to Date Total Return | -54.99% | |||
| 1-Year Total Return | -26.36% | |||
| 2-Year Total Return | 95.58% | |||
| 3-Year Total Return | 23.25% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -64.38% | |||
| 52-Week Low % Change | 11.49% | |||
| Price | EWTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $38.12 | |||
| 52-Week Low Price | $12.18 | |||
| 52-Week Low Price (Date) | Apr 02, 2025 | |||
| 52-Week High Price (Date) | Nov 11, 2024 | |||
| Valuation | EWTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.29B | |||
| Enterprise Value | 827.45M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.45 | |||
| Earnings Per Share Growth | -7.71% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 2.80 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $12.17 | |||
| Enterprise Value/EBITDA (TTM) | -5.28 | |||
| Enterprise Value/EBIT | -5.21 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | EWTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 94.72M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | EWTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 720-262-7002 | |||
| Address | 1715 38th Street Boulder, CO 80301 | |||
| Website | edgewisetx.com | |||
| Country | United States | |||
| Year Founded | 2017 | |||
| Profitability | EWTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | EWTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -24.01% | |||
| Return on Equity | -- | |||
| Income Statement | EWTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -156.76M | |||
| EBIT (TTM) | -158.83M | |||
| Net Income (TTM) | -133.81M | |||
| Net Income Avl. to Common (TTM) | -133.81M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -31.58% | |||
| EPS Diluted (TTM) | -1.45 | |||
| EPS Diluted Growth (Q YOY) | 10.03% | |||
| Balance Sheet | EWTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 470.17M | |||
| Cash Per Share (Q) | $4.96 | |||
| Total Current Assets (Q) | 475.48M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 459.22M | |||
| Current Ratio (Q) | 19.928 | |||
| Book Value Per Share (Q) | $4.84 | |||
| Total Assets (Q) | 486.82M | |||
| Total Current Liabilities (Q) | 23.86M | |||
| Total Debt (Q) | 4.74M | |||
| Total Liabilities (Q) | 27.60M | |||
| Total Common Equity (Q) | 459.22M | |||
| Cash Flow | EWTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -184.66M | |||
| Cash from Financing (TTM) | 249.25M | |||
| Net Change in Cash (TTM) | -44.43M | |||
| Levered Free Cash Flow (TTM) | -63.22M | |||
| Cash from Operations (TTM) | -109.03M | |||
